person · Reporting owner
Williams Donald Allen
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adhera Therapeutics, Inc.MRNA · Entity 127789 | Director | April 16, 2018 | April 18, 2018 |
| Alphatec Holdings, Inc.ATEC · Entity 4720 | Director | June 16, 2021 | June 21, 2021 |
| Forte Biosciences, Inc.FBRX · Entity 9529 | Director | August 20, 2024 | August 22, 2024 |
| PALISADE BIO, INC.PALI · Entity 5803 | Director | October 01, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adhera Therapeutics, Inc.
Report date April 16, 2018 · Filed April 18, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series E Convertible Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.50 | Direct | 18 |
Reported balance
After 2018-04-16 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-04-16 · Grant · Acquired 18 · Balance 18 F1: In connection with the closing of the issuer's private placement of shares of its Series E Convertible Preferred Stock and warrants to purchase shares of its common stock (the "Offering"), which occurred on April 16, 2018, the issuer and the reporting person agreed that the issuer would satisfy all accrued and unpaid fees owed by the issuer to the reporting person for services as a member of the issuer's Board of Directors prior to January 1, 2018 by the issuance by the issuer to the reporting person of 18 shares of Series E Preferred Stock and warrants to purchase 135,000 shares of common stock. F2: Each outstanding share of Series E Preferred Stock shall be converted into common stock on the earliest to occur of: (i) any date more than 30 trading days after the closing of the Offering that the closing price of the common stock on each of the 30 days immediately prior to such conversion exceeds $5.00; (ii) the three year anniversary of the closing of the Offering; and (iii) the date on which the holders of a majority of the outstanding shares of Series E Preferred Stock elect to convert all of the outstanding shares of Series E Preferred Stock. |
| Warrants to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.55 | Direct | 135,000 |
Reported balance
After 2018-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-04-16 · Grant · Acquired 135,000 · Balance 135,000 F1: In connection with the closing of the issuer's private placement of shares of its Series E Convertible Preferred Stock and warrants to purchase shares of its common stock (the "Offering"), which occurred on April 16, 2018, the issuer and the reporting person agreed that the issuer would satisfy all accrued and unpaid fees owed by the issuer to the reporting person for services as a member of the issuer's Board of Directors prior to January 1, 2018 by the issuance by the issuer to the reporting person of 18 shares of Series E Preferred Stock and warrants to purchase 135,000 shares of common stock. F3: The warrants expire on the five year anniversary of the closing of the Offering. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the closing of the issuer's private placement of shares of its Series E Convertible Preferred Stock and warrants to purchase shares of its common stock (the "Offering"), which occurred on April 16, 2018, the issuer and the reporting person agreed that the issuer would satisfy all accrued and unpaid fees owed by the issuer to the reporting person for services as a member of the issuer's Board of Directors prior to January 1, 2018 by the issuance by the issuer to the reporting person of 18 shares of Series E Preferred Stock and warrants to purchase 135,000 shares of common stock.
F2: Each outstanding share of Series E Preferred Stock shall be converted into common stock on the earliest to occur of: (i) any date more than 30 trading days after the closing of the Offering that the closing price of the common stock on each of the 30 days immediately prior to such conversion exceeds $5.00; (ii) the three year anniversary of the closing of the Offering; and (iii) the date on which the holders of a majority of the outstanding shares of Series E Preferred Stock elect to convert all of the outstanding shares of Series E Preferred Stock.
F3: The warrants expire on the five year anniversary of the closing of the Offering.
Alphatec Holdings, Inc.
Report date June 16, 2021 · Filed June 21, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 134,728 |
Reported balance
After 2021-06-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-06-16 · Grant · Acquired 10,221 · Balance 134,728 F1: On June 16, 2021, issuer granted to the reporting person 10,221 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the earlier of (a) the next annual meeting of stockholders and (b) the death or resignation of the reporting person. In the event of death or resignation of the reporting person, the grant will vest pro-rated based on the number of actual days served by the reporting person from the time of the grant to such death or resignation, divided by 365. |
Filing footnotes · ownership attribution and instrument terms
F1: On June 16, 2021, issuer granted to the reporting person 10,221 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the earlier of (a) the next annual meeting of stockholders and (b) the death or resignation of the reporting person. In the event of death or resignation of the reporting person, the grant will vest pro-rated based on the number of actual days served by the reporting person from the time of the grant to such death or resignation, divided by 365.
Forte Biosciences, Inc.
Report date August 20, 2024 · Filed August 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.34 · Expires 2034-08-20 | Direct | 50,000 |
Reported balance
After 2024-08-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-20 · Grant · Acquired 50,000 · Balance 50,000 F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean August 20, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean August 20, 2024.
PALISADE BIO, INC.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,590,294 |
Ending reported balance
After 2026-10-02 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-01 · Purchase · Acquired 10,000 · Balance 1,580,294 Row 2 · 2026-10-02 · Purchase · Acquired 10,000 · Balance 1,590,294 |
| Common StockSEC Table I · non-derivative | IndirectBy Reporting Person's Defined Benefit Plan | 3,000 |
Reported balance
Holding disclosure · report date 2026-10-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2026 Filed Oct 5, 2026 21:20 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock | 10,000 | $1.46 | $14,600.00 |
DisclosureSEC source: 0001493152-26-045772 · ownership.xml · nonDerivative · entry 2 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,590,294 Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 21:20 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock | 10,000 | $1.42 | $14,200.00 |
DisclosureSEC source: 0001493152-26-045772 · ownership.xml · nonDerivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,580,294 Read SEC document |
| June 10, 2026 Filed Jun 13, 2026 00:12 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionRestricted Stock Units · Derivative | 60,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-028572 · ownership.xml · derivative · entry 4 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,334 Underlying: Common Stock · 60,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. F3 · derivative.exercise_date: The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. F3 · derivative.expiration_date: The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| June 10, 2026 Filed Jun 13, 2026 00:12 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionCommon Stock | 60,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-028572 · ownership.xml · nonDerivative · entry 2 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,570,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The Reporting Person was granted RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested on June 10, 2026. F2 · price: The Reporting Person was granted RSUs. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs vested on June 10, 2026. Read SEC document |
| June 10, 2026 Filed Jun 13, 2026 00:12 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantCommon Stock | 1,498,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-26-028572 · ownership.xml · nonDerivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,509,628 F1 · kind: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2027 annual meeting of stockholders or (ii) the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2027 annual meeting of stockholders or (ii) the anniversary of June 10, 2026, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:05 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock | 5,000 | $1.67 | $8,356.00 |
DisclosureSEC source: 0001493152-26-003078 · ownership.xml · nonDerivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,728 Read SEC document |
| January 09, 2026 Filed Jan 14, 2026 02:43 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock | 5,000 | $1.88 | $9,400.00 |
DisclosureSEC source: 0001493152-26-002107 · ownership.xml · nonDerivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,728 Read SEC document |
| October 06, 2025 Filed Oct 8, 2025 21:48 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 1,538,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-017481 · ownership.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,538,700 Underlying: Common Stock · 1,538,700 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. F2 · derivative.exercise_date: The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, which shall be satisfied on the earlier of (i) the date of the next annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. F2 · derivative.expiration_date: The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, which shall be satisfied on the earlier of (i) the date of the next annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| October 06, 2025 Filed Nov 7, 2025 01:21 UTC Amendment | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 182,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-021134 · ownership.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,000 Underlying: Common Stock · 182,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock, provided that, until such time as the Issuer has sufficient shares of Issuer common stock reserved under its 2021 Equity Incentive Plan (the "Plan") to issue upon settlement of all outstanding grants thereunder, the RSUs may be settled upon vesting in cash. F2 · shares: This amended Form 4 is being filed to correct the previously reported grant amount of 1,538,700 RSUs to the Reporting Person. The Issuer has rescinded the grant of 1,356,700 RSUs of the previously reported grant of 1,538,700 RSUs. F3 · derivative.exercise_date: The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. F3 · derivative.expiration_date: The RSUs are subject to a service-based vesting requirement and shall vest in three equal annual installments, with the first installment vesting on the earlier of (i) the date of the 2026 annual meeting of stockholders or (ii) the anniversary of October 6, 2025, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| September 04, 2025 Filed Sep 5, 2025 13:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantPhantom Units · Derivative | 64,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-012693 · ownership.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,400 Underlying: Common Stock · 64,400 shares Expires not disclosed F1 · derivative.exercise_price: Each Phantom Unit is the economic equivalent of one share of the Issuer's common stock. F2 · derivative.exercise_date: The Phantom Units vest in three equal annual installments beginning on August 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date F3 · derivative.exercise_date: Vested Phantom Units shall be settled solely in cash based on the fair market value of an equal number of shares of the Issuer's common stock on the earliest to occur of any of the following events: (a) termination of the Reporting Person's continuous service with the Issuer; (b) a Liquidity Change in Control (as defined in the Phantom Unit Plan) of the Issuer; or (c) 7th anniversary of the grant date. F2 · derivative.expiration_date: The Phantom Units vest in three equal annual installments beginning on August 5, 2026, subject to the Reporting Person's continuous service through each applicable vesting date F3 · derivative.expiration_date: Vested Phantom Units shall be settled solely in cash based on the fair market value of an equal number of shares of the Issuer's common stock on the earliest to occur of any of the following events: (a) termination of the Reporting Person's continuous service with the Issuer; (b) a Liquidity Change in Control (as defined in the Phantom Unit Plan) of the Issuer; or (c) 7th anniversary of the grant date. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 21:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionComon Stock, par value $0.01 | 388 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-047363 · ownership.xml · nonDerivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 728 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the issuance of common stock upon the full vesting and settlement of outstanding restricted stock units granted on November 21, 2023. F1 · price: Represents the issuance of common stock upon the full vesting and settlement of outstanding restricted stock units granted on November 21, 2023. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 20:07 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.34 | $0.00 |
DisclosureSEC source: 0001415889-24-022000 · form4-08222024_080837.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-08-20 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean August 20, 2024. Read SEC document |
| July 11, 2024 Filed Jul 16, 2024 00:10 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantCommon Stock Options · Derivative | 2,100 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001493152-24-027907 · ownership.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,100 Underlying: Common Stock · 2,100 shares Expires 2034-07-11 F1 · security: Represents partial compensation for services as a director pursuant to Issuer's non-employee director compensation policy, consisting of 2,100 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan. F2 · security: The grants vest fully on the one (1) year anniversary of the grant date. F3 · security: Each option represents the right to purchase one share of common stock at the exercise price. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 01:40 UTC | PALISADE BIO, INC. PALI · Entity 5803 | Exercise / conversionComon Stock, par value $0.01 | 340 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-023612 · ownership.xml · nonDerivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 340 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on June 11, 2023. F1 · shares: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on June 11, 2023. F1 · price: Represents the issuance of common stock upon the vesting and settlement of outstanding restricted stock units for the restricted stock units granted on June 11, 2023. Read SEC document |
| May 28, 2024 Filed May 29, 2024 19:47 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseComon Stock, par value $0.01 | 1,000 | $4.86 | $4,863.00 |
DisclosureSEC source: 0001493152-24-021777 · ownership.xml · nonDerivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 F1 · shares: Reporting Person purchased 1,000 shares of Common Stock of Issuer at a price per share of $4.863 on May 28, 2024. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 13:30 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock, par value $0.01 | 10,000 | $0.61 | $6,050.00 |
DisclosureSEC source: 0001493152-24-004565 · ownership.xml · nonDerivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Reporting Person's Defined Benefit Plan Disclosed balance after: 30,000 F1 · shares: Reporting Person purchased 10,000 shares of Common Stock of Issuer at a price per share of $0.605 on January 31, 2024. F1 · price: Reporting Person purchased 10,000 shares of Common Stock of Issuer at a price per share of $0.605 on January 31, 2024. Read SEC document |
| November 21, 2023 Filed Nov 24, 2023 21:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantCommon Stock Options · Derivative | 6,880 | $0.00 Strike: $0.59 | $0.00 |
DisclosureSEC source: 0001493152-23-042660 · ownership.xml · derivative · entry 2 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,880 Underlying: Common Stock · 6,880 shares Expires 2033-11-21 F1 · security: Represents supplemental grant issued to non-employee members of Board of Directors of Issuer, which includes 5,820 restricted stock units and 6,880 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan, as amended, and were approved by the Issuer's Compensation Committee. F2 · security: The grants vest fully on the one (1) year anniversary of the grant date. F5 · security: Each option represents the right to purchase one share of common stock at the exercise price. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. Read SEC document |
| November 21, 2023 Filed Nov 24, 2023 21:00 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 5,820 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-042660 · ownership.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,820 Underlying: Common Stock · 5,820 shares Expires not disclosed F1 · security: Represents supplemental grant issued to non-employee members of Board of Directors of Issuer, which includes 5,820 restricted stock units and 6,880 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan, as amended, and were approved by the Issuer's Compensation Committee. F2 · security: The grants vest fully on the one (1) year anniversary of the grant date. F3 · security: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_price: The grants vest fully on the one (1) year anniversary of the grant date. F3 · shares: Each restricted stock unit represents the right to receive, at settlement, one share of common stock. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. F4 · derivative.expiration_date: N/A. Read SEC document |
| September 27, 2023 Filed Sep 29, 2023 13:25 UTC | PALISADE BIO, INC. PALI · Entity 5803 | PurchaseCommon Stock, par value $0.01 | 20,000 | $0.54 | $10,800.00 |
DisclosureSEC source: 0001493152-23-034756 · ownership.xml · nonDerivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Reporting Person's Defined Benefit Plan Disclosed balance after: 20,000 F1 · shares: Reporting Person purchased 20,000 shares of Common Stock of Issuer at a price per share of $0.54 on September 27, 2023. F1 · price: Reporting Person purchased 20,000 shares of Common Stock of Issuer at a price per share of $0.54 on September 27, 2023. Read SEC document |
| September 19, 2023 Filed Sep 20, 2023 21:54 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001209191-23-050195 · doc4.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2033-09-19 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean September 19, 2023. Read SEC document |
| July 31, 2023 Filed Aug 2, 2023 22:02 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantCommon Stock | 59,405 | $1.01 | $59,999.05 |
DisclosureSEC source: 0001209191-23-044285 · doc4.xml · nonDerivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,405 Read SEC document |
| June 11, 2023 Filed Jun 13, 2023 22:43 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantCommon Stock Options · Derivative | 12,160 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001493152-23-021129 · ownership.xml · derivative · entry 2 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,160 Underlying: Common Stock · 12,160 shares Expires 2033-06-11 F1 · security: Represents partial compensation for services as a director pursuant to Issuer's director compensation policy, which includes 5,100 restricted stock units and 7,000 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan. In addition, Reporting Person received, per its election, an additional 5,160 common stock purchase options as a discretionary grant. F2 · security: The grants vest fully on the one (1) year anniversary of the grant date. F5 · security: Each option represents the right to purchase one share of common stock at the exercise price. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. Read SEC document |
| June 11, 2023 Filed Jun 13, 2023 22:43 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantRestricted Stock Units · Derivative | 5,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-021129 · ownership.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,100 Underlying: Common Stock · 5,100 shares Expires not disclosed F1 · security: Represents partial compensation for services as a director pursuant to Issuer's director compensation policy, which includes 5,100 restricted stock units and 7,000 common stock purchase options. The grants were issued from Issuer's 2021 Equity Incentive Plan. In addition, Reporting Person received, per its election, an additional 5,160 common stock purchase options as a discretionary grant. F3 · security: Each restricted stock unit represents the right to receive one share of common stock. F2 · derivative.exercise_price: The grants vest fully on the one (1) year anniversary of the grant date. F3 · shares: Each restricted stock unit represents the right to receive one share of common stock. F2 · derivative.exercise_date: The grants vest fully on the one (1) year anniversary of the grant date. F4 · derivative.expiration_date: N/A Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 21:14 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-22-033633 · doc4.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean June 1, 2022. Read SEC document |
| February 23, 2022 Filed Feb 24, 2022 22:08 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.27 | $0.00 |
DisclosureSEC source: 0001209191-22-012749 · doc4.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-02-23 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through the applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the one (1) year anniversary of the Date of Grant. "Date of Grant" shall mean February 23, 2022. Read SEC document |
| November 18, 2021 Filed Feb 10, 2022 23:23 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantStock Option (right to buy) · Derivative | 48,340 | $0.00 Strike: $2.32 | $0.00 |
DisclosureSEC source: 0001209191-22-008581 · doc4.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,340 Underlying: Common Stock · 48,340 shares Expires 2032-11-17 F1 · derivative.exercise_date: 25% of the shares of Common Stock subject to the Option shall vest on each quarterly anniversary of the grant date over a one-year period. Read SEC document |
| June 16, 2021 Filed Jun 21, 2021 18:17 UTC | Alphatec Holdings, Inc. ATEC · Entity 4720 | GrantCommon Stock | 10,221 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-006874 · edgar.xml · nonDerivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,728 F1 · security: On June 16, 2021, issuer granted to the reporting person 10,221 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the earlier of (a) the next annual meeting of stockholders and (b) the death or resignation of the reporting person. In the event of death or resignation of the reporting person, the grant will vest pro-rated based on the number of actual days served by the reporting person from the time of the grant to such death or resignation, divided by 365. F1 · shares: On June 16, 2021, issuer granted to the reporting person 10,221 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the earlier of (a) the next annual meeting of stockholders and (b) the death or resignation of the reporting person. In the event of death or resignation of the reporting person, the grant will vest pro-rated based on the number of actual days served by the reporting person from the time of the grant to such death or resignation, divided by 365. F1 · price: On June 16, 2021, issuer granted to the reporting person 10,221 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the earlier of (a) the next annual meeting of stockholders and (b) the death or resignation of the reporting person. In the event of death or resignation of the reporting person, the grant will vest pro-rated based on the number of actual days served by the reporting person from the time of the grant to such death or resignation, divided by 365. F1 · balance_after: On June 16, 2021, issuer granted to the reporting person 10,221 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the earlier of (a) the next annual meeting of stockholders and (b) the death or resignation of the reporting person. In the event of death or resignation of the reporting person, the grant will vest pro-rated based on the number of actual days served by the reporting person from the time of the grant to such death or resignation, divided by 365. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 23:29 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $35.54 | $0.00 |
DisclosureSEC source: 0000899243-21-021413 · doc4.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-05-28 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over the twelve (12) months following the Date of Grant, provided that the shares subject to the option shall be fully vested on the date of the Issuer's next annual stockholder meeting. "Date of Grant" shall mean May 28, 2021. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:56 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantStock Option (Right to Buy) · Derivative | 4,406 | Not disclosed Strike: $26.85 | Not disclosed |
DisclosureSEC source: 0001209191-21-029081 · doc4.xml · derivative · entry 2 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,406 Underlying: Common Stock · 4,406 shares Expires 2030-07-10 F4 · price: Received in the Merger in exchange for a stock option to acquire 162,069 shares of LBS common stock for $0.73 per share. F3 · derivative.exercise_date: The stock option vests according to the following schedule: 25% of the shares underlying the option vests on grant date and the remaining 75% vests in three equal quarterly installments thereafter beginning on September 30, 2020. Read SEC document |
| April 27, 2021 Filed Apr 29, 2021 21:56 UTC | PALISADE BIO, INC. PALI · Entity 5803 | GrantStock Option (Right to Buy) · Derivative | 10,203 | Not disclosed Strike: $41.20 | Not disclosed |
DisclosureSEC source: 0001209191-21-029081 · doc4.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,203 Underlying: Common Stock · 10,203 shares Expires 2029-06-19 F2 · price: Received in exchange for a stock option to acquire 375,250 shares of common stock of Leading BioSciences, Inc. ("LBS") for $1.12 per share, pursuant to the Agreement and Plan of Merger, dated December 16, 2020, among Seneca Biopharma Inc., Townsgate Acquisition Sub 1, Inc. and LBS (the "Merger"). Per the terms of the Merger, each share of LBS's common stock was converted into the right to receive 0.02719 shares of Seneca's common stock. In the Merger, the name of the Issuer was changed from Seneca Biopharma, Inc. to Palisade Bio, Inc. F1 · derivative.exercise_date: The stock option vested in four equal quarterly installments from June 30, 2019. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 21:52 UTC | Alphatec Holdings, Inc. ATEC · Entity 4720 | GrantCommon Stock | 26,956 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-007661 · edgar.xml · nonDerivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,507 F1 · security: On June 17, 2020, issuer granted to the reporting person 26,956 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the 12 month anniversary of the grant date. F1 · shares: On June 17, 2020, issuer granted to the reporting person 26,956 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the 12 month anniversary of the grant date. F1 · price: On June 17, 2020, issuer granted to the reporting person 26,956 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the 12 month anniversary of the grant date. F1 · balance_after: On June 17, 2020, issuer granted to the reporting person 26,956 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. The restricted stock units vest on the 12 month anniversary of the grant date. Read SEC document |
| June 15, 2020 Filed Jun 18, 2020 00:56 UTC | Forte Biosciences, Inc. FBRX · Entity 9529 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0000899243-20-016938 · doc4.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2030-06-15 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2017 Equity Incentive Plan) through each applicable vesting date, the shares subject to the option shall vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the Date of Grant. "Date of Grant" shall mean June 15, 2020. Read SEC document |
| June 21, 2019 Filed Jun 25, 2019 21:48 UTC | Alphatec Holdings, Inc. ATEC · Entity 4720 | GrantCommon Stock | 18,086 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-008111 · edgar.xml · nonDerivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,519 F1 · security: On June 21, 2019, issuer granted to the reporting person 18,086 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. F2 · security: The restricted stock units vest on the earlier of (i) the 12 month anniversary of the grant date and (ii) the date of issuer's next annual meeting of stockholders. F1 · shares: On June 21, 2019, issuer granted to the reporting person 18,086 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. F2 · shares: The restricted stock units vest on the earlier of (i) the 12 month anniversary of the grant date and (ii) the date of issuer's next annual meeting of stockholders. F1 · balance_after: On June 21, 2019, issuer granted to the reporting person 18,086 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. F2 · balance_after: The restricted stock units vest on the earlier of (i) the 12 month anniversary of the grant date and (ii) the date of issuer's next annual meeting of stockholders. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 00:06 UTC | Alphatec Holdings, Inc. ATEC · Entity 4720 | PurchaseCommon Stock | 4,000 | $2.47 | $9,890.00 |
DisclosureSEC source: 0001179110-19-003808 · edgar.xml · nonDerivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,433 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.45 to $2.48, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. Read SEC document |
| July 30, 2018 Filed Aug 2, 2018 01:19 UTC | Alphatec Holdings, Inc. ATEC · Entity 4720 | GrantCommon Stock | 20,492 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-010085 · edgar.xml · nonDerivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,433 F1 · date: On July 30, 2018, issuer granted to the reporting person 20,492 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. F2 · date: The restricted stock units vest on the earlier of (i) the 12 month anniversary of the grant date and (ii) the date of issuer's next annual meeting of stockholders. F1 · shares: On July 30, 2018, issuer granted to the reporting person 20,492 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. F2 · shares: The restricted stock units vest on the earlier of (i) the 12 month anniversary of the grant date and (ii) the date of issuer's next annual meeting of stockholders. F1 · balance_after: On July 30, 2018, issuer granted to the reporting person 20,492 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of issuer's common stock. F2 · balance_after: The restricted stock units vest on the earlier of (i) the 12 month anniversary of the grant date and (ii) the date of issuer's next annual meeting of stockholders. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 21:40 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | GrantWarrants to Purchase Common Stock · Derivative | 135,000 | $0.00 Strike: $0.55 | $0.00 |
DisclosureSEC source: 0001493152-18-005445 · form4.xml · derivative · entry 2 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: common stock · 135,000 shares Expires not disclosed F1 · kind: In connection with the closing of the issuer's private placement of shares of its Series E Convertible Preferred Stock and warrants to purchase shares of its common stock (the "Offering"), which occurred on April 16, 2018, the issuer and the reporting person agreed that the issuer would satisfy all accrued and unpaid fees owed by the issuer to the reporting person for services as a member of the issuer's Board of Directors prior to January 1, 2018 by the issuance by the issuer to the reporting person of 18 shares of Series E Preferred Stock and warrants to purchase 135,000 shares of common stock. F3 · derivative.expiration_date: The warrants expire on the five year anniversary of the closing of the Offering. Read SEC document |
| April 16, 2018 Filed Apr 18, 2018 21:40 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | GrantSeries E Convertible Preferred Stock · Derivative | 18 | $5,000.00 Strike: $0.50 | $90,000.00 |
DisclosureSEC source: 0001493152-18-005445 · form4.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18 Underlying: common stock · 180,000 shares Expires not disclosed F1 · kind: In connection with the closing of the issuer's private placement of shares of its Series E Convertible Preferred Stock and warrants to purchase shares of its common stock (the "Offering"), which occurred on April 16, 2018, the issuer and the reporting person agreed that the issuer would satisfy all accrued and unpaid fees owed by the issuer to the reporting person for services as a member of the issuer's Board of Directors prior to January 1, 2018 by the issuance by the issuer to the reporting person of 18 shares of Series E Preferred Stock and warrants to purchase 135,000 shares of common stock. F2 · derivative.expiration_date: Each outstanding share of Series E Preferred Stock shall be converted into common stock on the earliest to occur of: (i) any date more than 30 trading days after the closing of the Offering that the closing price of the common stock on each of the 30 days immediately prior to such conversion exceeds $5.00; (ii) the three year anniversary of the closing of the Offering; and (iii) the date on which the holders of a majority of the outstanding shares of Series E Preferred Stock elect to convert all of the outstanding shares of Series E Preferred Stock. Read SEC document |
| January 03, 2018 Filed Jan 3, 2018 18:55 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | GrantOptions to purchase common stock · Derivative | 3,800 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001587074-18-000004 · primary_doc.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,800 Underlying: common stock · 3,800 shares Expires 2023-01-03 F1 · derivative.exercise_date: Options to purchase 1,900 shares of common stock are exercisable beginning on January 3, 2018, and options to purchase 1,900 shares of common stock are exercisable beginning on January 3, 2019. Read SEC document |
| April 25, 2017 Filed Jun 26, 2017 22:58 UTC | Alphatec Holdings, Inc. ATEC · Entity 4720 | GrantStock Option (right to buy) · Derivative | 28,090 | $0.00 Strike: $1.98 | $0.00 |
DisclosureSEC source: 0001179110-17-009624 · edgar.xml · derivative · entry 2 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,090 Underlying: Common Stock · 28,090 shares Expires 2027-04-25 F2 · derivative.exercise_date: The option vests 25% on the first anniversary of the grant date and thereafter in 36 equal monthly installments. Read SEC document |
| April 25, 2017 Filed Jun 26, 2017 22:58 UTC | Alphatec Holdings, Inc. ATEC · Entity 4720 | GrantCommon Stock | 18,939 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-009624 · edgar.xml · nonDerivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,941 F1 · shares: The shares vest in four equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| January 03, 2017 Filed Jan 4, 2017 18:27 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | GrantOptions to purchase common stock · Derivative | 81,000 | $0.00 Strike: $0.17 | $0.00 |
DisclosureSEC source: 0001493152-17-000149 · form4.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,000 Underlying: common stock · 81,000 shares Expires 2022-01-03 F1 · derivative.exercise_date: Options to purchase 40,500 shares of common stock are exercisable beginning on January 3, 2017 and options to purchase 40,500 shares of common stock are exercisable beginning on January 3, 2018. Read SEC document |
| December 12, 2016 Filed Dec 16, 2016 18:16 UTC | Alphatec Holdings, Inc. ATEC · Entity 4720 | GrantNQ Stock Option · Derivative | 3,303 | $4.43 Strike: $4.43 | $14,632.29 |
DisclosureSEC source: 0001350653-16-000123 · wf-form4_148191217752978.xml · derivative · entry 2 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,569 Underlying: Common Sock · 3,303 shares Expires 2026-12-12 F2 · price: The exercise price per share. F1 · derivative.exercise_date: The options are fully vested as of the grant date. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 17:31 UTC | Adhera Therapeutics, Inc. MRNA · Entity 127789 | GrantOptions to purchase common stock · Derivative | 35,000 | $0.00 Strike: $0.10 | $0.00 |
DisclosureSEC source: 0001493152-16-015244 · form4.xml · derivative · entry 1 Williams Donald Allen · CIK 0001620013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common stock · 35,000 shares Expires 2021-11-15 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.